Holen Sie sich die Stockscreener-App
33.97
0.59%
-0.20
Handel nachbörslich:
33.95
-0.02
-0.06%
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
PHVS|Pharvaris NV|Price:34.170|Chg%:+0.910 - TradingKey
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Pharvaris Director Sells Shares Worth $1.33 Million - sekbernews.id
Pharvaris N.V. Revenue Breakdown – NASDAQ:PHVS - TradingView
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? - The Motley Fool
Pharvaris publishes review on bradykinin B2 receptor research - Investing.com
Pharvaris publishes review on bradykinin B2 receptor research By Investing.com - Investing.com Canada
Here's why Pharvaris NV (PHVS) is a great momentum stock to buy - MSN
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Morgan Stanley Maintains Pharvaris N.V. (PHVS) Overweight Recommendation - MSN
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance
PHVS Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pharvaris stock with Overweight rating - Investing.com
Wells Fargo initiates Pharvaris stock with Overweight rating By Investing.com - Investing.com Canada
Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event - Stock Titan
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Zacks Investment Research
Form 144 Pharvaris N.V. For: 13 July By Investing.com - Investing.com Nigeria
Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares - Stock Titan
FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics
FDA accepts Pharvaris NDA for oral HAE attack treatment drug - Investing.com
FDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.com - Investing.com Nigeria
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
PHVSPharvaris NV Latest SEC Filings - Finviz
Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com
Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan
Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan
Pharvaris (PHVS) Faces Resistance as Stock Slips 2.5%Time Weighted Price - dars.gov.et
PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan
PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan
Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan
Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan
PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan
PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan
8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan
Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView
Pharvaris (PHVS) Gains 2.13% as Shares Approach Key Resistance LevelDividend Stock Picks - dars.gov.et
Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily
PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et
Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS) - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Price to sales forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to book forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Enterprise value to EBITDA forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to earnings forward of Pharvaris N.V. – LS:A2QNWS - TradingView
[144] Pharvaris N.V. SEC Filing - Stock Titan
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):